David V. Goeddel, Ph.D.

Tim Kutzkey, Ph.D.

Peter Svennilson

David Baltimore, Ph.D.

Michael S. Brown, M.D.

Joseph L. Goldstein, M.D.

Tom Maniatis, Ph.D.

Roger Perlmutter, M.D., Ph.D.

James Evangelista

Sue Murakami

Grant Heidrich

Dr. Goeddel co-founded Tularik in November 1991, was Vice President of Research until 1996 and CEO from April 1996 - August, 2004, when Tularik was acquired by Amgen. He served as Amgen’s first Senior Scientific Vice President until May, 2006. Prior to Tularik, he was the first scientist hired by Genentech, Inc. and from 1978 to 1993 served in various positions, including Fellow, Staff Scientist and Director of Molecular Biology. His pioneering work in the fields of gene cloning and expression of human proteins has been the basis for five significant marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon-alpha, interferon-gamma and tissue plasminogen activator. Dr. Goeddel has received numerous scientific awards including the Scheele Medal, the Eli Lilly Award in Biological Chemistry, the Inventor of the Year Award, the Jacob Heskel Gabbay Award, the Howley Prize for Arthritis Research and the Warren Alpert Foundation Prize. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.

Board of Directors: Constellation Pharmaceuticals, Igenica (Chairman), NGM Biopharmaceuticals (Chairman), Nurix, Peloton Therapeutics
Scientific Advisory Board: Igenica, Peloton Therapeutics